Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, Alliance, and Financing activity.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

With an increasing emphasis on tight glycemic control in diabetes care, innovative devices could play a big role, but diabetes is a deceptively complex market. Innovative companies need to differentiate themselves, yet not venture too far outside existing industry dynamics. As the first real-time continuous glucose monitors come to market, a handful of start-ups hopes to be ready for the second generation. Many of these are taking a side excursion into the market for in-hospital glucose monitoring, once a sleepy market but now growing rapidly as outcomes data shows reduced mortality and morbidty in intensively managed hyperglycemic hospital patients.

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Personalized Medicine, features profiles of Aureon Biosciences Corp., Favrille Inc. and Xanthus Life Sciences Inc. Plus these Start-Ups across Health Care: Cameron Health Inc., Dynogen Pharmaceuticals Inc., Functional Genetics Inc. and Tensys Medical Inc.